216 related articles for article (PubMed ID: 16505737)
1. Estimated effectiveness and cost-effectiveness of federally funded prevention efforts on gonorrhea rates in the United States, 1971-2003, under various assumptions about the impact of prevention funding.
Chesson HW
Sex Transm Dis; 2006 Oct; 33(10 Suppl):S140-4. PubMed ID: 16505737
[TBL] [Abstract][Full Text] [Related]
2. The president's fiscal year 2007 initiative for human immunodeficiency virus counseling and testing expansion in the United States: a scenario analysis of its coverage, impact, and cost-effectiveness.
Holtgrave DR
J Public Health Manag Pract; 2007; 13(3):239-43. PubMed ID: 17435490
[TBL] [Abstract][Full Text] [Related]
3. Does funding for HIV and sexually transmitted disease prevention matter? Evidence from panel data.
Chesson HW; Harrison P; Scotton CR; Varghese B
Eval Rev; 2005 Feb; 29(1):3-23. PubMed ID: 15604117
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of sexually transmitted infections: incidence and direct medical cost of Chlamydia, gonorrhea, and syphilis among Illinois adolescents and young adults, 2005-2006.
Pultorak E; Wong W; Rabins C; Mehta SD
Sex Transm Dis; 2009 Oct; 36(10):629-36. PubMed ID: 19955874
[TBL] [Abstract][Full Text] [Related]
5. The economic value of reductions in gonorrhea and syphilis incidence in the United States, 1990-2003.
Chesson HW; Gift TL; Pulver AL
Prev Med; 2006 Nov; 43(5):411-5. PubMed ID: 16901533
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus counseling, testing, referral, and partner notification services. A cost-benefit analysis.
Holtgrave DR; Valdiserri RO; Gerber AR; Hinman AR
Arch Intern Med; 1993 May; 153(10):1225-30. PubMed ID: 8388208
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the routine, occupation-based gonorrhea and syphilis screening program in Moscow, Russia: an analysis of sexually transmitted infection prevalence and cost-effectiveness.
Kourbatova EV; Akovbyan VA; Chesson HW; Lytkina IN; Dmitriev GA; Tikhonova LI; Koubanova AA; Petukhova II; Latypova MF; Aboymova OA; Lewis JS; Ryan CA; Shakarishvili A
Sex Transm Dis; 2008 May; 35(5):453-60. PubMed ID: 18434940
[TBL] [Abstract][Full Text] [Related]
8. Decreasing age disparities in syphilis and gonorrhea incidence rates in the United States, 1981--2005.
Chesson HW; Zaidi AA; Aral SO
Sex Transm Dis; 2008 Apr; 35(4):393-7. PubMed ID: 18362861
[TBL] [Abstract][Full Text] [Related]
9. Sexually transmitted diseases: meeting the 1990 objectives--a challenge for the 1980s.
Wiesner PJ; Parra WC
Public Health Rep; 1982; 97(5):409-16. PubMed ID: 6896921
[TBL] [Abstract][Full Text] [Related]
10. Medicaid-based child restraint system disbursement and education and the vaccines for children program: comparative cost-effectiveness.
Goldstein JA; Winston FK; Kallan MJ; Branas CC; Schwartz JS
Ambul Pediatr; 2008; 8(1):58-65. PubMed ID: 18191783
[TBL] [Abstract][Full Text] [Related]
11. Methods for Sexually Transmitted Disease Prevention Programs to Estimate the Health and Medical Cost Impact of Changes in Their Budget.
Chesson HW; Ludovic JA; Berruti AA; Gift TL
Sex Transm Dis; 2018 Jan; 45(1):2-7. PubMed ID: 29240632
[TBL] [Abstract][Full Text] [Related]
12. Examining the impact of federally-funded syphilis elimination activities in the USA.
Chesson H; Owusu-Edusei K
Soc Sci Med; 2008 Dec; 67(12):2059-62. PubMed ID: 18952341
[TBL] [Abstract][Full Text] [Related]
13. The Estimated Impact of Implementing a Funding Allocation Formula on the Number of Gonorrhea Cases in the United States, 2014 to 2018.
Aslam MV; Chesson H
Sex Transm Dis; 2021 Sep; 48(9):663-669. PubMed ID: 34110755
[TBL] [Abstract][Full Text] [Related]
14. Show me the money: state contributions toward STD prevention, 2007.
Meyerson BE; Gilbert LK
J Public Health Manag Pract; 2010; 16(3):232-9. PubMed ID: 20357609
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
[TBL] [Abstract][Full Text] [Related]
16. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
[TBL] [Abstract][Full Text] [Related]
17. [Incremental cost effectiveness of multifocal cataract surgery].
Pagel N; Dick HB; Krummenauer F
Klin Monbl Augenheilkd; 2007 Feb; 224(2):101-9. PubMed ID: 17309005
[TBL] [Abstract][Full Text] [Related]
18. Social capital and rates of gonorrhea and syphilis in the United States: spatial regression analyses of state-level associations.
Semaan S; Sternberg M; Zaidi A; Aral SO
Soc Sci Med; 2007 Jun; 64(11):2324-41. PubMed ID: 17400352
[TBL] [Abstract][Full Text] [Related]
19. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
20. Ryan White CARE Act Title IV programs: a preliminary characterization of benefits and costs.
Abramowitz S; Greene D
AIDS Public Policy J; 2005; 20(3-4):108-25. PubMed ID: 17624034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
